Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
5.75M
-
Shares change
-
-993K
-
Total reported value, excl. options
-
$11.7M
-
Value change
-
-$1.82M
-
Number of buys
-
8
-
Number of sells
-
-11
-
Price
-
$2.03
Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q2 2023
24 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q2 2023.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.75M shares
of 26M outstanding shares and own 22.08% of the company stock.
Largest 10 shareholders include Novo Holdings A/S (2.4M shares), Redmile Group, LLC (2.07M shares), Bruce & Co., Inc. (772K shares), Artal Group S.A. (200K shares), Alpha Wave Global, LP (109K shares), MILLENNIUM MANAGEMENT LLC (80.4K shares), PNC Financial Services Group, Inc. (65K shares), Tower Research Capital LLC (TRC) (12K shares), GEODE CAPITAL MANAGEMENT, LLC (11.1K shares), and HRT FINANCIAL LP (10.7K shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.